Evofem Biosciences Reports Material Agreement
Ticker: EVFM · Form: 8-K · Filed: Apr 3, 2025 · CIK: 1618835
| Field | Detail |
|---|---|
| Company | Evofem Biosciences, Inc. (EVFM) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-news
TL;DR
Evofem signed a new deal on 3/28, filing it 4/3.
AI Summary
Evofem Biosciences, Inc. filed an 8-K on April 3, 2025, reporting a material definitive agreement entered into on March 28, 2025. The filing also includes financial statements and exhibits. The company was formerly known as Neothetics, Inc. before changing its name on September 5, 2014.
Why It Matters
This filing indicates a significant new agreement for Evofem Biosciences, which could impact its business operations and financial future.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Neothetics, Inc. (company) — Former company name
- March 28, 2025 (date) — Date of earliest event reported
- April 3, 2025 (date) — Filing date
- September 5, 2014 (date) — Date of name change
FAQ
What is the nature of the material definitive agreement entered into by Evofem Biosciences?
The filing does not specify the details of the material definitive agreement, only that one was entered into on March 28, 2025.
When was the 8-K filing submitted to the SEC?
The 8-K filing was submitted on April 3, 2025.
What was Evofem Biosciences' former name?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc.
When did the company change its name from Neothetics, Inc.?
The company changed its name on September 5, 2014.
What is the principal executive office address for Evofem Biosciences?
The principal executive offices are located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 3, 2025 regarding Evofem Biosciences, Inc. (EVFM).